Inovio Pharmaceuticals, Inc.
(NASDAQ : INO)

( )
INO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
TMOThermo Fisher Scientific, Inc. 1.29%427.741.0%$611.97m
ABTAbbott Laboratories 0.96%104.440.8%$543.13m
ISRGIntuitive Surgical, Inc. 2.88%693.162.4%$502.54m
DHRDanaher Corp. 1.22%209.690.7%$459.49m
MDTMedtronic Plc 0.43%103.600.6%$458.62m
BDXBecton, Dickinson & Co. 0.41%224.991.0%$391.59m
INOInovio Pharmaceuticals, Inc. -28.34%12.145.9%$341.55m
DXCMDexCom, Inc. -0.54%400.197.9%$332.41m
SYKStryker Corp. 1.02%207.091.3%$287.02m
BSXBoston Scientific Corp. 1.77%38.001.0%$286.72m
QDELQuidel Corp. 0.95%198.647.7%$263.05m
VARVarian Medical Systems, Inc. -0.04%171.939.1%$253.67m
BAXBaxter International, Inc. -0.08%79.581.8%$242.31m
ALGNAlign Technology, Inc. 1.55%322.866.4%$232.00m
EWEdwards Lifesciences Corp. 0.48%77.820.4%$224.51m

Company Profile

Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company. It engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. The firm's drug candidates include SynCon immunotherapies which helps break the immune system’s tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.